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Background: Ubiquitin-specific protease 14 (USP14) is one of three proteasome-associated deubiquitinating enzymes
that remove ubiquitin from proteasomal substrates prior to their degradation. In vitro evidence suggests that inhibiting
USP14’s catalytic activity alters the turnover of ubiquitinated proteins by the proteasome, although whether protein
degradation is accelerated or delayed seems to be cell-type and substrate specific. For example, combined inhibition of
USP14 and the proteasomal deubiquitinating enzyme UCH37 halts protein degradation and promotes apoptosis in
multiple myeloma cells, whereas USP14 inhibition alone accelerates the degradation of aggregate-prone proteins in
immortalized cell lines. These findings have prompted interest in USP14 as a therapeutic target both inside and outside
of the nervous system. However, loss of USP14 in the spontaneously occurring ataxia mouse mutant leads to a
dramatic neuromuscular phenotype and early perinatal lethality, suggesting that USP14 inhibition may have adverse
consequences in the nervous system. We therefore expressed a catalytically inactive USP14 mutant in the mouse
nervous system to determine whether USP14’s catalytic activity is required for neuromuscular junction (NMJ) structure
and function.
Results: Mice expressing catalytically inactive USP14 in the nervous system exhibited motor deficits, altered NMJ
structure, and synaptic transmission deficits that were similar to what is observed in the USP14-deficient ataxia
mice. Acute pharmacological inhibition of USP14 in wild type mice also reduced NMJ synaptic transmission.
However, there was no evidence of altered proteasome activity when USP14 was inhibited either genetically or
pharmacologically. Instead, these manipulations increased the levels of non-proteasome targeting ubiquitin
conjugates. Specifically, we observed enhanced proteasome-independent ubiquitination of mixed lineage kinase
3 (MLK3). Consistent with the direct activation of MLK3 by ubiquitination, we also observed increased activation
of its downstrea targets MAP kinase kinase 4 (MKK4) and c-Jun N-terminal kinase (JNK). In vivo inhibition of JNK
improved motor function and synapse structure in the USP14 catalytic mutant mice.
Conclusions: USP14’s catalytic activity is required for nervous system structure and function and has an ongoing
role in NMJ synaptic transmission. By regulating the ubiquitination status of protein kinases, USP14 can coordinate the
activity of intracellular signaling pathways that control the development and activity of the NMJ.
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Protein ubiquitination is an exceptionally flexible post-
translational modification because ubiquitin can be con-
jugated onto substrates in different lengths and linkages,
enabling it to regulate a wide variety of signaling pathways
[1,2]. For example, lysine 63 (K63)- linked chains regulate
the endocytosis and sorting of plasma membrane receptors.
[3]. There is also an emerging link between K63-linked
ubiquitination and kinase activation [4,5], with K63-linked
chains serving as a scaffold for the recruitment of sig-
naling components or, in the case of MLK3, directly in-
ducing dimerization and kinase activation [6]. In contrast,
K48-linked ubiquitin chains target proteins for proteasomal
degradation.
USP14 is one of three proteasome-associated deubi-
quitinating enzymes (DUBs) that remove ubiquitin from
proteasomal substrates prior to their degradation, thus
terminating the ubiquitin signal and maintaining a stable
pool of free ubiquitin [7-9]. In addition, USP14’s catalytic
activity may alter the turnover of ubiquitinated proteins
by the proteasome in a cell-type and substrate specific
manner [10-13]. Combined inhibition of USP14 and the
proteasomal DUB ubiquitin C-terminal hydrolase 37
(UCH37) in multiple myeloma cells delays proteasome-
mediated protein degradation, halts the cell cycle, and
leads to tumor cell apoptosis [14]. In contrast, in immor-
talized cell lines, inhibition of USP14 appears to accelerate
the degradation of proteins known to aggregate in neuro-
logical diseases [11]. Additional proteolysis-independent
functions for USP14 have also been described, including
deconjugating K63-linked ubiquitin chains on Disheveled
2 [15] and controlling the cell-surface expression of
GABAA receptors [16].
Despite the growing interest in USP14 inhibition as a
treatment for neurological diseases ([11,17] but see [18])
and cancers [13,14,19,20], loss of USP14 in the spontan-
eously occurring ataxia (axJ) mouse mutant causes a
severe loss of mobility and early postnatal lethality [21].
The neuromuscular phenotype of the axJ mice is rescued
by neuronal-specific expression of USP14 [22], demon-
strating a critical need for USP14 in the nervous system. In
this study, we used genetic and pharmacological inhibition
of USP14 to investigate the contributions of USP14’s cata-
lytic activity to NMJ structure and function. Expression of
a catalytically inactive form of USP14 in the nervous
system caused developmental deficits in NMJ structure
and synaptic transmission. However, acute pharmacological
inhibition of USP14 at adult NMJs also significantly re-
duced synaptic transmission, indicating that USP14 partic-
ipates in dynamic ubiquitin signaling events that support
neurotransmitter release. This ubiquitin signaling appears
to be independent of proteasomal-mediated protein
degradation. Instead, our data suggest that USP14 dis-
assembles non-proteasomal-targeting ubiquitin chains andindicate that loss of USP14’s DUB activity leads to en-
hanced K63-linked ubiquitination of MLK3 and hyperacti-
vation of its signaling cascade. Inhibition of pJNK, which
is downstream of MLK3, significantly improved the motor
deficits and NMJ pathology caused by loss of USP14’s
DUB activity. These findings demonstrate that USP14 is
involved in regulating multiple ubiquitin signals in the
nervous system, ranging from acute ubiquitination for the
maintenance of synaptic activity to long-term control of
ubiquitin pools.
Results
TgUsp14CA displaces endogenous USP14 from the
proteasome without altering proteasome activity
To investigate the contributions of USP14’s DUB activity
to nervous system structure and function, we generated
transgenic mice expressing a catalytically inactive form
of USP14 in the nervous system. The coding sequence
for USP14’s active site cysteine was changed to an alanine
residue using PCR-site-directed mutagenesis, and the
resulting Usp14C114A cDNA was cloned behind the
neuronal Thy1.2 promoter (Figure 1A). Expression of this
transgene, referred to as TgUsp14CA, caused a robust
increase in USP14 expression in the spinal cords of both
wild type and USP14-deficient axJ mice (Figure 1B) that
was easily detectible by postnatal day (P) 8 (see Additional
file 1). Because reduced ubiquitin levels [23] and altered
NMJ structure [24] are observed in axJ mice prior to P8,
we chose to study the effects of TgUsp14CA in wild type
mice. Importantly, using RNA transcriptome analysis, we
determined that TgUsp14CA did not alter the expression
of endogenous Usp14 mRNA in the brains of wild type
mice, and that transgenic Usp14CA mRNA accounted for
90% of total Usp14 transcripts (Figure 1C). We therefore
interpreted the robust increase in USP14 abundance
observed in the brains and spinal cords of wild type
mice expressing TgUsp14CA (henceforth TgUsp14CA mice)
as evidence of USP14CA expression (see Additional file 1).
In contrast, USP14 abundance was not increased in
non-neuronal tissues of TgUsp14CA mice, indicating
that USP14CA was expressed exclusively in the nervous
system (Additional file 1). Overall, the localization and
abundance of USP14CA were consistent with what we
have previously observed when wild type USP14 is
expressed under the Thy1.2 promoter [22].
While USP14 can be found both free and bound to the
proteasome, its catalytic activity has only been observed
when associated with the proteasome [22]. We found
that expression of TgUsp14CA caused increased USP14
abundance in proteasome fractions isolated from the
brains of 4- to 6-week old mice that was similar to what
was observed when wild type USP14 was overexpressed
in the TgUsp14 mice (Figure 1D). To determine whether
USP14CA was the predominant USP14 species on
Figure 1 Transgenic expression of USP14CA in the nervous system. (A) Full length Usp14 cDNA containing a mutation of the active site
cysteine to alanine (C114A) was cloned behind the Thy1.2 promoter. (B) Representative immunoblot of spinal cord extracts taken from 4- to 6- week-old
wild type and axJ mice (± TgUsp14CA) mice using USP14-specific antisera. β-tubulin was included as a loading control. (C) Abundance of wild type Usp14
and transgenic Usp14CA transcripts obtained by RNA transcriptome analysis of brain tissue taken from 4- to 6-week-old wild type and TgUsp14CA mice.
(D) Representative immunoblots of USP14 in whole brain lysates and brain proteasome fractions from 4- to 6-week-old wild type, TgUsp14CA,
and TgUsp14 mice. β-tubulin was included as a loading control for whole brain and RPT1 was a loading control for the proteasome fraction.
TgUsp14 mice express wild type USP14 behind the Thy1.2 promoter. (E) Ubiquitin vinyl methyl ester (Ub-VME) assay for DUB activity in proteasome
fractions from the brains of 4- to 6-week-old wild type, TgUsp14, and TgUsp14CA mice. Ubiquitin is covalently attached to the active site cysteine of
USP14, resulting in a slower migrating USP14 species denoted as USP14-Ub-VME. The mutant USP14CA cannot be labeled by Ub-VME. (F) Relative
mRNA quantity of proteasome subunits and associated factors determined by qPCR, normalized to wild type (represented by dotted line on graph),
from spinal cords of 6-week-old wild type and TgUsp14CA mice. n = 3 mice per genotype, run in triplicate. Data are shown as mean ± SEM (G) Assay of
trypsin-like activity of proteasomes isolated from 4- to 6-week-old wild type and TgUsp14CA mice using the fluorogenic Boc-LRR-AMC substrate. n = 3
mice per genotype, and data are shown as mean ± SEM. See also Additional file 1.
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methyl-ester (Ub-VME) assay [25]. Ub-VME labels catalyt-
ically active USP14 by forming a covalent bond with its
active site cysteine residue, creating a shift in molecular
weight that can be detected by immunoblotting. Because
the active site cysteine is mutated to alanine in USP14CA,
it cannot be labeled by Ub-VME. As expected, when pro-
teasome fractions isolated from the brains of wild type
and TgUsp14 mice were incubated with Ub-VME, all
USP14 was labeled within 1 hr (Figure 1E). In contrast,
only minimal USP14 labeling was observed in protea-
somes isolated from TgUsp14CA mice, demonstratingthat USP14CA displaces endogenous USP14 from the
proteasome.
Because inhibition of Upb6, the yeast ortholog of
USP14, delays the degradation of ubiquitinated proteins
by the proteasome and induces increased transcription of
proteasomal subunits [10], we looked for signs of prote-
asome dysfunction in the nervous systems of TgUsp14CA
mice. In contrast to what is observed in yeast, we did not
observe transcriptional upregulation of components of the
proteasome’s catalytic core or regulatory particle in the
brains of TgUsp14CA mice (Figure 1F). Similarly, when
the chymotrypsin-like activity of proteasomes isolated
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proteasomes, the activity profile was identical (Figure 1G).
Therefore, expression of TgUsp14CA almost completely
eliminated the DUB activity of USP14 on the proteasome,
but did not cause proteasome stress.
TgUsp14CA reduces muscle mass, strength, and
coordination but does not cause early postnatal lethality
Unlike loss of neuronal USP14 in the axJ mice [21,22],
inhibition of USP14’s DUB activity in the nervous sys-
tem did not alter the lifespan of the TgUsp14CA mice
(Figure 2A). However, TgUsp14CA did have deficits in
muscle development, muscle strength, and motor coordin-
ation similar to what is observed in axJ mice, and could beFigure 2 Neuronal expression of USP14CA leads to decreased body w
for wild type, TgUsp14CA, TgUsp14, and axJ mice. TgUsp14 mice express wi
neuronal USP14 overexpression in TgUsp14CA mice. axJ mice have a 95% r
limb clasping in TgUsp14CA mice versus the typical splaying observed in 6-
muscle mass, (E) muscle strength and (F) motor performance of 2- to 24-w
assessed by a forelimb grip-force assay and motor performance was assess
as mean ± SEM. Symbols represent Mann-Whitney tests compared against
adjustment where appropriate; *p < 0.05, **p < 0.01, ***p < 0.001; n = at leaeasily distinguished from wild type littermates by 3 weeks
of age due to a resting tremor and hind limb clasping
upon tail suspension (Figure 2B). The TgUsp14CA mice
were significantly smaller than wild type mice by 12
weeks of age (Figure 2C), and had reduced muscle mass
(Figure 2D) and fore limb grip strength (Figure 2E) by
4 weeks of age. Similarly, 4-week-old TgUsp14CA mice
required more time than wild type controls to cross an
elevated beam, and 24-week-old TgUsp14CA mice were
completely unable to traverse the beam (Figure 2F). Be-
cause the deficits in body mass, muscle development,
and motor performance observed in the TgUsp14CA
mice were not replicated by overexpression of wild type
USP14 in the TgUsp14 mice, they were attributed toeight, muscle weight, and motor performance. (A) Survival curves
ld type USP14 under the Thy1.2 promoter and serve as a control for
eduction of USP14 in all tissues. (B) Tail suspension assays show hind
week-old wild type and TgUsp14 mice. Assays of (C) body mass, (D)
eek-old wild type, TgUsp14CA, and TgUsp14 mice. Muscle strength was
ed by time required to traverse an elevated beam. All data are shown
wild type and corrected for multiple comparisons with a Bonferonni
st 4 animals per genotype per time point.
Figure 3 (See legend on next page.)
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Figure 3 Expression of TgUsp14CA causes functional and structural deficits at the NMJ. (A) Example traces of MEPCs recorded from
diaphragms of 4- to 6-week-old wild type, axJ, and TgUsp14CA mice. (B) MEPC frequency in wild type (n = 56 endplates, 10 mice), TgUsp14CA
(n = 23 endplates, 4 mice), and axJ (n = 75 endplates, 10 mice) muscles. (C) MEPC amplitude in wild type (n = 45 endplates, 10 mice), TgUsp14CA
(n = 21 endplates, 4 mice) and axJ (n = 75 endplates, 10 mice). (D) MEPC decay constant in wild type (n = 42 endplates, 10 mice), TgUsp14CA
(n = 17 endplates, 4 mice) and axJ (n = 23 endplates, 10 mice) muscles. (E) Evoked EPC amplitudes in wild type (n = 55 endplates, 10 mice),
TgUsp14CA (n = 15 endplates, 4 mice) and axJ (n = 75 endplates, 10 mice) muscles. (F) Quantal content in wild type (n = 40 endplates, 10 mice),
TgUsp14CA (n = 15 endplates, 4 mice) and axJ (n = 59 endplates, 10 mice) muscles. (G) qPCR of AChR subunits in the gastrocnemius muscles
of 4-week-old wild type and TgUsp14CA mice. Data were normalized to wild type and n = at least 3 mice per genotype. All data in (B)-(G) are
shown as mean ± SEM. Symbols represent Mann-Whitney tests compared against wild type and corrected for multiple comparisons with a
Bonferonni adjustment. *p < 0.05, **p < 0.01, and ***p < 0.001. (H) Immunostaining of TA muscles from 4-week-old wild type and TgUsp14CA
mice. Axons were visualized via expression of YFP (green) under the neuronal Thy1.2 promoter and AChRs were labeled with rhodamine-conjugated
α-bungarotoxin (α-BTX, red). White arrows indicate ultra-terminal sprouting and blue arrows indicate axonal and terminal swellings, scale bars = 50 μm.
See also Additional file 2.
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overexpression.
USP14’s ubiquitin hydrolase activity supports NMJ
structure and function
The reduced muscle mass and motor coordination ob-
served in TgUsp14CA mice suggested that neuronal ex-
pression of catalytically-inactive USP14 caused deficits in
synaptic transmission similar to what we have previously
observed in the USP14-deficient axJ mice [21,24]. To test
this, we used two-electrode voltage clamp to record mini-
ature endplate currents (MEPCs) in diaphragm muscles
from 4- to 6-week-old wild type, axJ, and TgUsp14CA mice
(Figure 3A). Like the axJ mice, TgUsp14CA mice had a
marked reduction in frequency of MEPCs, and the ampli-
tude and decay constant of MEPCs were increased com-
pared to controls (Figure 3B-D).
A change in MEPC kinetics, such as the increased decay
constant observed in TgUsp14CA mice (Figure 3D), often
reflects a change in the properties of the postsynaptic re-
ceptor. When we examined expression of muscle acetyl-
choline receptor (AChR) subunits in 4-week-old mice, we
found a greater than 100-fold increase in transcripts of the
fetal AChR-γ subunit in TgUsp14CA gastrocnemius mus-
cles compared to wild type muscles (Figure 3G). Consist-
ent with the increased decay constant observed at the
TgUsp14CA NMJ, AChRs containing the γ-subunit have a
longer channel open time than receptors containing the
adult ε-subunit [26]. The γ-containing receptors and up-
regulation of the α- and ε- AChR subunits observed in the
TgUsp14CA mice are also observed following denervation
and nerve block [27], and may represent postsynaptic
compensation for reduced neurotransmission. However,
despite these postsynaptic compensations, the TgUsp14CA
endplates displayed reduced synaptic responses upon nerve
stimulation (Figure 3E) and decreased quantal content
(Figure 3F). We also observed significant pathology when
we examined NMJ structure using whole mount immuno-
staining of the tibialis anterior (TA) muscle. Presynaptic
swelling and ultra-terminal sprouting were detectable by 2weeks of age (see Additional file 2), and by 4 weeks of age,
57% of the TgUsp14CA terminals displayed focal swellings
and 56% had ultra-terminal sprouting (Figure 3H).
Acute inhibition of USP14 leads to reduced
neurotransmitter release at the NMJ
To differentiate between abnormal development and an
ongoing need for USP14’s DUB activity in synaptic trans-
mission at the adult NMJ, we measured spontaneous and
evoked transmission following acute treatment with the
USP14 inhibitor IU1 in phrenic nerve/diaphragm prepara-
tions from adult wild type and TgUsp14CA mice. Example
traces for each condition are shown in Figure 4A. IU1
treatment of wild type NMJs replicated the decrease in
MEPC frequency (Figure 4B) and the increase in the
MEPC decay constant (Figure 4D) observed in the axJ and
TgUsp14CA mice (Figure 3B and D). In contrast, we did
not observe any effect of IU1 treatment on TgUsp14CA
NMJs, indicating that the IU1-mediated alterations in syn-
aptic transmission were due to inhibition of USP14’s DUB
activity. Acute inhibition of USP14 in wild type mice also
recapitulated the deficits in EPC amplitude and quantal
content (Figure 4E and F) observed in TgUsp14CA mice
(Figure 3E and F). Only the increase in MEPC amplitude
observed in axJ and TgUsp14CA mice was not mimicked
by IU1 treatment (Figure 4C). These data indicate that the
synaptic deficits observed in TgUsp14CA mice are not due
to aberrant development, but rather reflect an ongoing
need for USP14’s DUB activity at the adult NMJ.
The increase in the MEPC decay constant in TgUsp14CA
mice was associated with increased expression of the fetal
AChR-γ subunit in gastrocnemius muscles (Figure 3G).
Similarly, 1 week of IU1 injections into the gastrocnemius
muscles of adult, wild type mice (Figure 4G) caused an
increase in AChR-γ abundance compared to what was
observed in vehicle-injected control muscles (Figure 4H),
indicating that USP14-inhibition at the adult NMJ is
sufficient to cause induction of the embryonic AChR-γ
subunit. We also examined NMJ structure following
IU1 treatment. Unlike in TgUsp14CA mice (Figure 3H),
Figure 4 (See legend on next page.)
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Figure 4 Acute inhibition of USP14 causes synaptic transmission deficits at the adult NMJ. (A) Example traces of MEPCs recorded from
diaphragm muscle fibers isolated from 4- to 6-week-old wild type (n = 10 endplates, 4 mice) and TgUsp14CA (n = 7 endplates, 3 mice) muscles in
the presence of vehicle or the USP14 inhibitor IU1. Quantitation of (B) MEPC frequency, (C) amplitude, and (D) decay constants in muscles from
wild type and TgUsp14CA muscles before (-) and after (+) 5 μM IU1 application. Quantitation of (E) EPC amplitude and (F) quantal content in wild
type muscles (n = 10 endplates, 4 mice) before (-) and after (+) addition of 5 μM IU1. In (B)-(F), symbols represent Wilcoxon matched-pairs signed
rank tests, where *p < 0.05 (G) Schematic of experimental design, where adult wild type mice (12- to 14-weeks-old) were given intramuscular
injections of 100 μL of 100 μM IU1 or vehicle every other day for 1 week, and (H) the abundance of AChR subunit mRNA in gastrocnemius
muscles was compared using qPCR. Data are shown as mean ± SEM and were normalized to vehicle treatment. n = 3 muscles per condition,
run in triplicate. (I) Whole mount immunostaining of gastrocnemius muscles from wild type mice given intramuscular injections of IU1 or vehicle as
described above. Endplates were labeled with rhodamine-conjugated α-BTX, and motor neurons were visualized via expression of YFP under the
Thy1.2 promoter. Scale bars = 50 μm.
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served in IU1-treated wild type mice, and the endplates
retained their mature, arborized appearance (Figure 4I).
These experiments demonstrate that abnormal terminal
structure is not a prerequisite for deficient synaptic trans-
mission, and suggests that these deficits may have distinct
underlying mechanisms.Inhibition of USP14’s DUB activity causes accumulation of
K63-linked ubiquitin chains
The role of USP14 in the maintenance of ubiquitin homeo-
stasis is well established, so we reasoned that aberrant
ubiquitin signaling might underlie the neuromuscular
phenotype of the TgUsp14CA mice and the synaptic
deficits caused by acute inhibition of USP14. Consistent
with USP14’s ubiquitin hydrolase activity, we found an
increase in ubiquitinated proteins in the spinal cords of
TgUsp14CA mice compared to controls and in cortical
neurons treated with IU1 (see Additional file 3).
Although we found no difference in the catalytic cap-
acity of TgUsp14CA and wild type proteasomes towards
the fluorogenic Boc-LRR-AMC substrate (Figure 1G), this
increase in ubiquitin conjugates was consistent with de-
creased turnover of ubiquitinated proteins by the prote-
asome. Because the Boc-LRR-AMC substrate is not
ubiquitinated and can bypass the proteasome’s regulatory
particle and enter the catalytic core directly, the turnover
of this substrate may not accurately reflect the turnover of
ubiquitinated proteins in vivo. However, when we mea-
sured the abundance of proteasomal-targeting K48-linked
ubiquitin conjugates, which serve as a robust and sensitive
marker of ubiquitin proteasome system function [28], we
found no difference between wild type and TgUsp14CA
spinal cords or between IU1- and vehicle-treated neurons
(Figure 5A and B). Instead, we observed increased K63-
linked ubiquitin conjugates in both TgUsp14CA spinal
cords and IU1-treated neurons (Figure 5C and D). K63-
linked ubiquitin chains do not appear to target proteins
for proteasomal degradation [29-31], but, instead, regulate
receptor internalization, endosomal sorting, and intracel-
lular signaling [29].USP14’s DUB activity regulates the MLK3 signaling cascade
K63-linked ubiquitination of MLK3 leads to dimerization
and auto-phosphorylation on threonine 277/serine 281 [6].
This auto-phosphorylation enables MLK3 to phosphorylate
mitogen-activated protein kinase kinase 4 (MKK4), which,
in turn, phosphorylates JNK. Because MLK3 is activated by
K63-linked ubiquitination and elevated pJNK has been
demonstrated to cause terminal swelling [32] and sprout-
ing [33] at the NMJ that is similar to what we observed in
the TgUsp14CA mice (Figure 3H), we investigated whether
this pathway was hyperactivated in the TgUsp14CA mice.
When we immunoprecipitated MLK3 from spinal cord ex-
tracts, we observed increased K63-linked ubiquitination
and enhanced serine/threonine phosphorylation of high
molecular weight MLK3 species in TgUsp14CA lysates
compared to wild type lysates (Figure 6A and B). We
also observed increased phosphorylation of MLK3’s
target MKK4, even though total MKK4 abundance
was decreased in TgUsp14CA mice relative to controls
(Figure 6C and D). Although we observed a significant de-
crease in Mkk4 mRNA in TgUsp14CA spinal cords com-
pared to wild type spinal cords (see Additional file 4), the
magnitude of the effect may not explain the 39% reduction
in MKK4 protein.
When compared to wild type mice, we observed in-
creased pJNK1/2 in spinal cord extracts of TgUsp14CA
and axJ mice and decreased pJNK1/2 in spinal cord ex-
tracts of TgUsp14 mice, (Figure 6E and F) indicating that
USP14’s DUB activity can bidirectionally modulate JNK
activation, likely by controlling MLK3 ubiquitination.
Notably, there was no change in the activation of the MAP
kinases p38 and ERK in the spinal cords of TgUsp14CA
mice compared to wild type mice, and, although pJNK can
induce cell death, there was no evidence of apoptosis in
spinal cords of TgUsp14CA mice (see Additional file 4).
We next performed whole mount immunostaining of TA
muscles of wild type and TgUsp14CA mice using an anti-
body against pJNK (Figure 6G and H) and found a signifi-
cant correlation between pJNK staining and TgUsp14CA
terminal pathology. In the TgUsp14CA mice, 94% of the
terminal swellings and 90% of the ultra-terminal sprouts
were pJNK positive.
Figure 5 Loss of USP14’s ubiquitin hydrolase activity results in accumulation of non-proteasomal associated ubiquitin conjugates.
(A) Representative immunoblot of spinal cord extracts from 4- to 6-week-old wild type and TgUsp14CA mice and cortical neurons treated with
vehicle or 20 μM IU1 for 24 h and probed with an antibody specific for K48-linked ubiquitin chains. (B) Quantitation of (A). (C) As in (A) except
with anti-K63-linked ubiquitin chain antibody. β-tubulin was used as a loading control in all experiments. (D) Quantitation of (D). Data are shown as
mean ± SEM, and n = at least 3 animals per genotype or condition run in duplicate. Symbols represent Mann-Whitney tests, where *p < 0.05
and **p < 0.01. See also Additional file 3.
Vaden et al. Molecular Neurodegeneration 2015, 10:3 Page 9 of 17
http://www.molecularneurodegeneration.com/content/10/1/3Elevated pJNK contributes to the structural and
functional deficits caused by loss of USP14’s DUB activity
Because excess pJNK at the NMJ has previously been
shown to cause motor endplate disease [33] and JNK
inhibition causes increased neurotransmitter release in
the central nervous system [34], we hypothesized that
the elevated pJNK observed in the TgUsp14CA spinal
cords and motor neuron terminals may have caused
deficits in NMJ structure and function. To test this, we ad-
ministered the JNK inhibitor SP600125 (SP) to 3-week-old
wild type and TgUsp14CA mice via intraperitoneal (IP)
injections. Daily IP injections were given at a dose of
16 mg/kg for 2 weeks, and control mice received an
equivalent volume of DMSO vehicle alone. SP inhibits
JNK by reversibly occupying its ATP binding pocket to
prevent kinase activity towards its substrates. Because
JNK is autophosphorylated, SP causes a reduction of
pJNK (Figure 7A) that is equivalent to the reduction of
activated JNK substrates [35]. On average, we observed
an approximately 30% reduction of pJNK in the spinal
cords of SP-treated mice compared to their vehicle-treated
counterparts (wild type: normalized pJNK abundance
1.01 ± 0.07 for vehicle-treated mice versus 0.71 ± 0.10 for
SP-treated mice, p < 0.01, Mann-Whitney test; TgUsp14CA:
1.03 ± 0.08 for vehicle-treated mice versus 0.67 ± 0.19 for
SP-treated mice, p < 0.01, Mann-Whitney test).Although we found no difference between the gastro-
cnemius muscle masses of wild type mice treated with SP
or vehicle alone, SP injections resulted in a significant in-
crease in the gastrocnemius mass of TgUsp14CA mice
(Figure 7B). This effect was observed in both male and fe-
male TgUsp14CA mice but was not significant when male
and female data were pooled because of the disparity in
muscle hypertrophy between genders. We also observed a
significant decrease in the abundance of AChR-γ mRNA
in SP-treated TgUsp14CA mice compared to vehicle-
treated TgUsp14CA mice (Figure 7C). Although there
was a significant upregulation of AChR-γ mRNA in SP-
treated wild type mice compared to vehicle-treated con-
trols, this effect cannot explain the decrease in AChR-γ
transcript abundance observed in TgUsp14CA mice. Be-
cause neuronal activity can promote muscle hypertrophy
and AChR transcript abundance is inversely proportional
to synaptic transmission, both the increase in muscle mass
and the decrease in AChR transcript abundance observed
in TgUsp14CA mice following JNK inhibition are consist-
ent with improved presynaptic NMJ function.
When we compared locomotion while exploring a novel,
open field, we found a significant decrease in distance
traveled (Figure 7D) and ambulatory velocity (Figure 7E)
in TgUsp14CA mice compared to wild type mice. How-
ever, SP-treated TgUsp14CA mice traveled as far and as
Figure 6 (See legend on next page.)
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Figure 6 Inhibition of USP14’s DUB activity leads to enhanced activation of the MLK3 signaling cascade. (A) Representative immunoprecipitates
(IP) of MLK3 from spinal cord lysates from 4- to 6-week-old wild type and TgUsp14CA mice, immunoblotted (IB) for K63-linked ubiquitin,
phospho-serine/threonine, and MLK3. (B) Quantitation of (A), K63- and pSer/Thr- modified MLK3 was normalized to total immunoprecipitated
MLK3. (C) Representative immunoblots of wild type and TgUsp14CA spinal cord extracts probed for pMKK4 and total MKK4. β-tubulin was used
as a loading control. (D) Quantitation of (C), pMKK4 was normalized to MKK4. (E) Representative immunoblots from spinal cords from 4- to 6-week-old
wild type, TgUsp14CA, axJ, and TgUsp14 mice, probed for pJNK1/2 and total JNK1/2. JNK 1 and 2 migrate to 46 and 54 kDa, respectively. β-tubulin was
used as a loading control. (F) Quantitation of (E), pJNK was normalized to JNK and quantitation includes both the 46 and 54 kDa bands. Data in (B), (D),
and (F) are shown as mean ± SEM, and n = 3 animals per genotype. Symbols represent Mann-Whitney tests compared against wild type mice
and corrected for multiple comparisons with a Bonferonni adjustment where appropriate; *p < 0.05, **p < 0.01, ***p < 0.001. (G) Representative
images of whole-mount immunostaining of TA muscles from 4-week-old wild type and TgUsp14CA mice using a pJNK antibody (blue). AChRs
were labeled with rhodamine-conjugated α-BTX (red), and motor neuron axons were visualized via expression of YFP under the Thy1.2 promoter (green).
Scale bars = 50 μm. (H) As in (G), except that scale bars = 20 μm. See also Additional file 4.
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In the more demanding rotarod assay, the performance
of the SP-treated TgUsp14CA mice was improved over
vehicle-treated TgUsp14CA mice, but was still significantly
worse than wild type mice (Figure 7F). We next used whole
mount immunostaining to determine if the improvements
in NMJ function observed in the TgUsp14CA mice follow-
ing SP treatment were accompanied by improved NMJ
structure. We found that, while the NMJs of SP-treated
TgUsp14CA mice were still abnormal compared to wild
type mice, there was an appreciable decrease in presynap-
tic swelling and an increase in endplate arborization com-
pared to vehicle-treated TgUsp14CA mice (Figure 7G).
Discussion
The purpose of this study was to determine whether
USP14’s catalytic activity is required for NMJ function
and to investigate the effects of USP14 inhibition on
proteasomal-dependent and –independent ubiquitin signal-
ing in the nervous system. Indeed, our results demonstrate
that USP14’s ubiquitin hydrolase activity modulates NMJ
development and synaptic transmission (Figures 3 and 4)
and regulates proteasomal-independent ubiquitin signaling
(Figures 5 and 6). We observed enhanced K63-linked
ubiquitination of MLK3 and hyperactivation of its down-
stream kinase JNK in the spinal cords of mice expressing
catalytically-inactive USP14 (Figure 6), and JNK inhibition
significantly improved both NMJ structure and motor
function in these mice (Figure 7), demonstrating that
the regulation of pJNK by USP14 is critical to nervous
system structure and function. In addition, we uncovered
an ongoing need for USP14’s DUB activity at adult NMJs
by demonstrating that the synaptic transmission deficits in
mice expressing USP14CA (Figure 5) were replicated by
acute inhibition of USP14 (Figure 4).
USP14 regulates proteasome-independent ubiquitin
signaling
The increases in ubiquitin conjugates observed in the spinal
cords of TgUsp14CA mice and in neuronal cultures when
USP14 is pharmacologically inhibited (see Additional file 3)mimic the effects on ubiquitin conjugates when the prote-
asome is inhibited [29,30]. However, the level of K48-linked
ubiquitin conjugates was unchanged in spinal cords from
TgUsp14CA mice compared to wild type mice and in cor-
tical neurons with and without IU1 (Figure 5A and B). Be-
cause K48-linked ubiquitin chains are a robust biomarker
of ubiquitin proteasome system function [28], and we found
no difference in the catalytic capacity of TgUsp14CA and
wild type proteasomes in vitro (Figure 1G), it is unlikely that
USP14 inhibition in the nervous system causes global
alterations in proteasome activity. Instead, we observed
an increase in K63-linked ubiquitin conjugates, which
do not accumulate following proteasome inhibition [29,30],
in both TgUsp14CA spinal cords and IU1-treated cortical
neurons (Figure 5C and D), suggesting that USP14 disas-
sembles non-proteasomal-targeting ubiquitin chains.
Expression of catalytically inactive USP14 in the nervous
systems of TgUsp14CA mice led to enhanced K63-linked
ubiquitination of MLK3 (Figure 6A and B), which has
previously been demonstrated to induce its dimerization,
auto-phosphorylation, and ability to phosphorylate MKK4
[6]. Consistent with this finding, we observed enhanced
phosphorylation of MLK3 (Figure 6A and B) and MKK4
(Figure 6C and D), as well as MKK4’s target JNK (Figure 6E
and F), in TgUsp14CA spinal cords. We also observed
prominent pJNK immunoreactivity in the swollen ter-
minals and within the ultra-terminal sprouts of TgUsp14CA
motor neurons (Figure 6G). In fact, treatment with the JNK
inhibitor SP600125 improved the muscle development
(Figure 7B), motor function (Figure 7D-F), and NMJ struc-
ture (Figure 7G) of the TgUsp14CA mice, even though we
began administration of the drug after the neuromuscular
phenotype was established (Additional file 2). More robust
JNK inhibition or beginning JNK inhibitor treatment at an
earlier age may have led to a more complete rescue of the
TgUsp14CA phenotype. Alternatively, the JNK pathway
may be one of multiple pathways that are regulated by
USP14’s catalytic activity. Support for the later explanation
comes from studies of the Drosophila highwire (hiw) mu-
tant, which has NMJ pathology and synaptic transmission
deficits that are similar to what we observed in TgUsp14CA
Figure 7 (See legend on next page.)
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Figure 7 Inhibition of pJNK improves the structural and functional deficits caused by inhibition of USP14’s DUB activity. (A) Representative
immunoblots of pJNK1/2 and JNK1/2 in spinal cords from 5-week-old wild type or TgUsp14CA mice following 2 weeks of IP injections of the
JNK inhibitor SP600125 (SP, +) or vehicle control (DMSO, -). β-tubulin was used as a loading control. Wild type mice given SP had pJNK levels
that were 71.2 ± 10.3% (p < 0.01, Mann-Whitney test) of what was observed in vehicle-treated wild type controls and SP-treated TgUsp14CA
mice had pJNK levels that were 66.6 ± 19.4% (p < 0.01, Mann-Whitney test) of vehicle-treated TgUsp14CA mice. (B) Gastrocnemius muscle
masses from male wild type or TgUsp14CA mice treated with vehicle alone (-) or SP (+) as described above. The same effect was observed in
female mice. (C) Relative AChR-γ mRNA abundance in gastrocnemius muscles. (D) Total distance travelled and (E) ambulatory velocity during
10 min in an open field. (F) Latency to fall from beam in the rotarod assay. For (B)-(F), all data are shown as mean ± SEM and n = 5 to 7 animals per
condition. Symbols represent Mann-Whitney tests corrected for multiple comparisons with a Bonferonni adjustment, where *p < 0.05, **p < 0.01,
and ***p < 0.001. (G) High magnification images of whole-mount immunostaining of TA muscles from mice described above. AChRs were
labeled with rhodamine-conjugated α-BTX (red), and motor neuron axons were visualized via expression of YFP under the Thy1.2 promoter
(green). Scale bars = 20 μm.
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cade in the hiw mutants corrects their NMJ pathology, but
their deficits in synaptic transmission persist.
USP14 has an ongoing role in synaptic transmission
We observed decreased MEPC frequency, EPC amplitude,
and quantal content at the NMJs of TgUsp14CA and axJ
mice (Figure 3A-F). Surprisingly, these deficits were mim-
icked by acute inhibition of USP14 at the NMJs of adult,
wild type mice (Figure 4A-F), likely indicating that USP14
has an ongoing role in synaptic transmission and that the
synaptic deficits in TgUsp14CA and axJ mice do not arise
from aberrant development. This conclusion is supported
by the finding that intramuscular injections of IU1 were
sufficient to cause alterations in AChR mRNA expression
but did not alter NMJ structure (Figure 4G-I), suggest-
ing that the structural and functional deficits at the
TgUsp14CA NMJs arise through different mechanisms.
Because synaptic proteins are turned over very slowly
in vivo, with an average turnover rate of 9 days [36],
and we found no evidence of proteasome dysfunction
in the TgUsp14CA mice or in IU1-treated neurons, the
rapid effects of IU1 on synaptic transmission are unlikely
to result from altered protein turnover. Instead, the rapid
effect of USP14 inhibition on MEPC frequency, the accu-
mulation of K63-linked chains upon USP14 inhibition
(Figure 6), and the regulation of JNK phosphorylation
by USP14 activity (Figure 7E and F) all support a model
in which USP14 dynamically deubiquitinates proteins
to affect their activity and not their abundance.
Conclusion
In this study, we demonstrated that USP14’s catalytic
activity is required for NMJ structure and function, and
provided evidence that USP14 regulates non-proteasomal
ubiquitin signaling in the nervous system. Although our
results are consistent with a recently published report
demonstrating that USP14 removes K63-linked ubiquitin
chains from Dvl2 [15], both studies raise the question of
how a proteasome-associated DUB could disassemble
proteasome-independent ubiquitin chains. Further studywill be required to determine if proteasome-bound USP14
can interact with K63-linked ubiquitin chains or, alterna-
tively, whether USP14’s DUB activity can be stimulated by
a novel binding partner, allowing it to be active when not
bound to the proteasome. In either case, our findings
demonstrate a novel role for USP14 and establish non-
canonical ubiquitin signaling as an important contribu-




C57BL/6J mice (wild type),Usp14axJ mice (Jackson Labora-
tories, Bar Harbor, MA) Thy1-YFP mice (16JRS, Jackson
Laboratories), transgenic mice expressing wild type USP14
(TgUsp14) [22], and transgenic mice expressing catalytic-
ally inactive USP14 (TgUsp14CA) have been maintained
in our breeding colony at the University of Alabama at
Birmingham, which is fully accredited by the Association
for Assessment and Accreditation of Laboratory Animal
Care International. All mouse lines were maintained on
a C57BL/6J background. Homozygous Usp14axJ mice
(which we refer to as axJ mice) were generated by inter-
crossing heterozygous axJ siblings. Research was conducted
without bias toward the sex of animals used for each study,
and male and female mice were used equally. All research
complied with the United States Animal Welfare Act and
other federal statutes and regulations relating to animals
and experiments involving animals and adhered to princi-
ples stated in the Guide for the Care and Use of Laboratory
Animals, United States National Research Council.
Construction of TgUsp14CA transgene
The full-length Usp14 cDNA, including the Usp14 Kozak
consensus sequence, was generated by using reverse
transcription-PCR (RT-PCR). USP14’s active site cysteine
(C114) was replaced with an alanine residue via PCR
site-directed mutagenesis. The cDNA was cloned into
the XhoI site of the pThy1.2 expression cassette (gift
from Dr. Pico Caroni at the Friedrich Institute, Basel,
Switzerland). The transgene was excised from the vector
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via standard procedures.
RNA transcriptome analysis
Total RNA was isolated from hippocampal lysates of 4-
week-old wild type and TgUsp14CA mice using RNA-
STAT60 (Tel-Test, Friendswood, TX). Poly(A) RNAs
were subsequently purified using an RNeasy Mini Kit
(Qiagen, Valencia, CA). cDNAs were generated and
paired-end sequencing was performed at Hudson Alpha
(Huntsville, AL).
Neuronal culture
Dissociated cortical cultures were prepared as described
[37]. Cultured neurons were treated with the USP14 in-
hibitor IU1 (20 μM) or an equivalent volume of vehicle
(DMSO) at 10 to 11 days in vitro, and protein was har-
vested 24 h later as described below.
Isolation of proteins
Mice 4- to 6- weeks of age were deeply anesthetized via
isoflurane prior to rapid decapitation. Tissues were re-
moved and homogenized in 1 to 3 mL of buffer containing
50 mM Tris, 150 mM NaCl, 5 mM MgCl2, 2 mM N-
ethylmaleimide, 0.5% SDS, Complete protease inhibitors
(Roche, Indianapolis, IN) and phosphatase inhibitor cock-
tail I (Sigma Aldrich, St. Louis, MO), pH 7.5. PR-619 (Life
Sensors, Malvern, PA) was added to a final concentra-
tion of 50 μM to inhibit a wide range of DUBs. After
homogenization, tissues were centrifuged at 17,000 × g
for 10 min at 4°C, and supernatants were removed and
immediately frozen at –80°C. Protein concentrations
were determined by using the bicinchoninic acid (BCA)
protein assay kit from Pierce (Rockford, IL).
Isolation of proteasomes and assays of proteasome activity
Proteasomes were isolated and assayed as described [9].
Immunoblotting
Protein electrophoresis and blotting was performed as
described [24]. Immunoblots probed for ubiquitin were
pretreated with 0.1% gluteraldehyde for 20 min prior to
blocking.
Immunoprecipitation
Proteins were isolated as described above in a modified
RIPA buffer containing 0.5% SDS and heated to 95°C for
5 min. Protein lysates were diluted 1:10 in a buffer con-
taining 25 mM Tris and 150 mM NaCl with a pH of 7.2
and incubated with 10 μg of MLK3 antibody overnight
at 4°C with constant agitation. The antibody/antigen
complex was added to 100 μL of Immobilized Protein
A/G resin slurry (Thermo Scientific, Waltham, MA) and
incubated with constant agitation at 4°C for 6 hours.Immunoprecipitates were collected by centrifugation
according to manufacturer instructions.
Antibodies
The following antibodies were used: USP14 [9]; β-tubulin
(Developmental Studies Hybridoma Bank, Iowa City, IA);
Rpt1 and MLK3 (Santa Cruz Biotechnologies, Dallas, TX);
Ubiquitin (UAB Hybridoma Facility, Birmingham, AL),
K48 Ubiquitin and K63 Ubiquitin (Millipore, Billerica,
MA); pMKK4, MKK4, pJNK, and JNK (Cell Signaling
Technology, Danvers, Massachusetts).
Quantitation of immunoblots
Blots were quantitated using ImageJ software (NIH,
Bethesda, MD). Each value represents the average and
standard error from at least two blots using at least
three different animals of each genotype.
Labeling of proteasome-associated DUBs
Activity of proteasomal DUBs was assayed as previously
described [22].
Immunocytochemistry (ICC)
ICC of PFA-fixed brain sections was performed as de-
scribed previously [38]. Briefly, following perfusion with
Tyrode’s solution and 4% PFA, serial coronal sections of
brain (50 μm) were prepared, and free-floating immuno-
histochemistry was performed. Spinal cords were paraf-
fin embedded. USP14 was detected using Alexa Fluor anti-
rabbit 594 antibody (Invitrogen, Carlsbad, CA). Sections
were washed in PBST containing DAPI (Invitrogen) to de-
tect nuclei. Free-floating sections were mounted on gelati-
nized slides and dehydrated in graded ethanol and xylenes.
Coverslips for all sections were secured in Prolong-gold
anti-fade mounting media (Invitrogen). TUNEL staining
was performed using the Roche TUNEL labeling kit per
manufacturer instructions (Roche Diagnostics Corporation,
Indianapolis, IN).
Grip strength test
Forelimb grip strength was determined using an animal
grip strength system (SDI, San Diego, CA). Each trial
consisted of five repetitions of this assay (n > 5 mice per
genotype per time point).
Elevated beam assay
Ability to traverse an elevated beam 2 cm in diameter
was assessed as previously described [22], n > 5 mice per
genotype per time point.
Rotarod assay
Motor coordination was tested by placing mice on a rotat-
ing rod (ENV-575, Med Associates, St. Albans, VT), which
accelerated from 3.5 rpm to 35 rpm over a 5-min period.
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by 1 h, and the individual trials for each animal were
averaged.
Open field assay
Animals were handled 1 day prior to open field testing.
Locomotor activity was measured in an open field chamber
(43.2 cm × 43.2 cm × 30.5 cm) for 15 min by an automated
video tracking system. The first 5 min were not analyzed to
account for habituation to the chamber.
NMJ immunostaining and confocal imaging
Whole mount immunostaining of the tibialis anterior (TA)
muscle was performed as described [23], with minor modi-
fications. The TA muscle was immersed in ice-cold PBS
containing 2% PFA for 1 h following dissection and imme-
diately teased into thin bundles. Muscle bundles were then
transferred to PBS containing 1% PFA and 1% Triton and
permeabilized overnight at 4°C with constant rocking.
To improve visualization of axons and ultra-terminal
sprouting, all mice used for NMJ immunostaining car-
ried the Thy1-YFP transgene in addition to the transgene
of interest. For pJNK immunostaining, muscle bundles
were incubated with primary antibody (pJNK, #81E11,
Cell Signaling Technology, Danvers, MA) for 5 days at
4°C with constant rocking. Images were captured using
a Zeiss LSM 510 Meta confocal microscope (Carl Zeiss,
Oberkochen, Germany).
Quantitative PCR
RNA isolation and quantitative PCR (qPCR) were per-
formed as described [23]. Individual gene assay kits were
purchased from Applied Biosystems for each of the RNAs
analyzed. n = at least 3 animals per genotype per time point
run in triplicate.
Electrophysiology
Two-electrode voltage clamp was performed as described
[24]. Diaphragms, with ribs and intact phrenic nerves, were
dissected from 5- to 6-week-old mice. All experiments
were performed at room temperature. For experiments
using IU1, measurements were taken in the presence of
vehicle alone prior to the introduction of 20 μM IU1
into the perfusing solution.
Intramuscular injections of IU1
Adult mice (12- to 14-weeks old) were lightly anesthetized
with isoflurane for injections into the gastrocnemius
muscle. Injections (100 μL) contained IU1 (100 μM) or ve-
hicle with 0.1% India blue ink, to ensure correct injection
location, and 0.05 mg/kg RIMADYL (Pfizer, New York
City, NY), to reduce discomfort, in sterile PBS. Each
animal (n = 3) received vehicle injection and IU1 injection
into the left and right gastrocnemius muscles, respectively.Intraperitoneal injections of SP600125
3-week-old wild type and TgUsp14CA mice were given
daily intraperitoneal injections of the JNK inhibitor
SP600125 (Fisher Scientific, Rockford, IL) for two weeks.
SP600125 was dissolved in DMSO at a concentration
of 91 mM and this solution was directly administered
at a dose of 16 mg/kg using a 25 μL Hamilton syringe
(Hamilton Company, Reno, NV). This procedure was
used to minimize the injection volume, as SP600125 is
not soluble in aqueous solutions and DMSO was not
tolerated at higher doses. Animals were weighed every
other day to adjust doses and to monitor potential ad-
verse effects of the injections. At the doses given, both
DMSO and SP600125 were well tolerated.Additional files
Additional file 1: Figure 1. USP14CA is expressed specifically in the
nervous system. Description of Data: (A) Developmental time course of
USP14 expression in spinal cords of wild type (-) and TgUsp14CA (+) mice
on postnatal days (P) 1-180 showing robust expression of the transgene
by P8. β-tubulin was included as a loading control. (B) Representative
immunoblots of USP14 from 4- to 6-week old wild type (-) and TgUsp14CA
(+) mice demonstrating neuronal expression of the transgene. USP14
overexpression is assumed to reflect transgene expression. β-tubulin was
included as a loading control (C) Representative immunostaining for USP14
(red) and DAPI (blue) in cerebral cortices and spinal cords of 8-week-old wild
type and TgUsp14CA mice. Scale bar = 100 μm.
Additional file 2: Figure3. TgUsp14CA mice have abnormal NMJ
structure starting at 2 weeks of age. Description of data: (A) Whole-mount
immunostaining of TA muscles from wild type and TgUsp14CA mice in
1- and 2-week-old. Motor neuron axons were stained with antibodies
against neurofilament and synaptophysin (green), and AChRs were labeled
with rhodamine-conjugated α-bungarotoxin (α-BTX, red). White arrows
indicate ultra-terminal sprouting and blue arrows indicate axonal swellings,
scale bars = 50 μm.
Additional file 3: Figure 5. Genetic inactivation and pharmacological
inhibition of USP14’s ubiquitin hydrolase activity lead to increased ubiquitin
conjugates. Description of data: (A) Representative immunoblot from spinal
cords of wild type, TgUsp14CA, TgUsp14, and axJ mice probed for ubiquitin.
β-tubulin was used as a loading control. (B) Representative immunoblot of
cortical neurons from wild type mice treated with vehicle (DMSO) or 20 μM
IU1 for 24 h.
Additional file 4: Figure 6. No evidence of cell death in TgUsp14CA
spinal cord. Description of data: (A) Relative abundance of Mkk4 mRNA in
spinal cords from 4- to 6- week-old wild type and TgUsp14CA mice. n = 3
animals per genotype, run in triplicate. (B) Representative immunoblots of
p-p38 MAP kinase, p38 MAP kinase, pERK1/2, and ERK1/2 in spinal cords
from 4- to-6 week-old wild type and TgUsp14CA mice. β-tubulin was used
as a loading control. (C) Quantitation of (B), pERK quantitation includes both
the 42 and 44 kDa bands. (D) TUNEL staining in spinal cord sections taken
from 8-week-old wild type and TgUsp14CA mice. Brain slices from wild
type mice were treated with DNase 1 to generate the positive control.
Scale bar = 50 μm.Abbreviations
USP14: Ubiquitin-specific protease 14; NMJ: Neuromuscular junction; JNK: c-Jun
N-terminal kinase; K48: Ubiquitin chain linked through internal lysine 48;
K63: Ubiquitin chain linked through internal lysine 63; MLK3: Mixed lineage
kinase 3; DUB: Deubiquitinating enzyme; axJ: USP14 deficient ataxia mice;
TgUsp14CA: Transgenic mice expressing inactive USP14C114A under Thy1.2
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